Lower Vitamin D Linked to Mood and Cognitive Impairment in Adults Over 85 With Diabetes
核心洞察
A cross-sectional study of 188 adults aged 85 and older with type 2 diabetes (搜索) found the lowest serum 25-hydroxyvitamin D levels in those with both depressive symptoms (搜索) and mild cognitive impairment (搜索) (13.86 ng/mL).
Lower vitamin D remained independently associated with comorbid depressive symptoms (搜索) and MCI after adjustment (aOR = 0.773, 95% CI 0.61–0.97, P = 0.03).
The authors describe this as the first study to assess vitamin D levels in this specific oldest-old diabetic population, but emphasize the findings show association, not causation.
A study of adults aged 85 and older reveals how vitamin D, metabolic health, depressive symptoms (搜索), and cognition intersect in one of diabetes care's most vulnerable populations. Published online as an unedited "Article in Press" manuscript in the journal Scientific Reports, the cross-sectional study examined 188 individuals with type 2 diabetes (搜索) (T2D), using serum 25-hydroxyvitamin D [25(OH)D] levels alongside standardized neuropsychological and metabolic evaluations.
The findings revealed that participants with both depressive symptoms (搜索) and mild cognitive impairment (搜索) (MCI) exhibited the lowest serum vitamin D concentrations. Lower serum 25(OH)D remained independently associated with having both conditions after adjustment for selected demographic and clinical factors. The authors note that these findings support further investigation of vitamin D as a correlate of mood and cognitive health, but do not establish its predictive or therapeutic value.
Study Design and Population
The study sample comprised 188 outpatients with T2D, all described by the authors as Caucasian (mean age = 87.3 years). Participants were consecutively recruited from a single diabetes outpatient clinic in Lodz, Poland, during the winter season to reduce seasonal variation in vitamin D levels. People with diagnosed depression or dementia were excluded.
Based on GDS-30 screening and a MoCA-based MCI assessment incorporating European Alzheimer's Disease Consortium criteria, participants were categorized into four groups: depressive symptoms (搜索) alone (n = 25), MCI alone (n = 52), comorbid depressive symptoms and MCI (n = 38), and a T2D comparison group without depressive symptoms or MCI (n = 73).
Participant evaluations were conducted in two parts. First, researchers collected morning fasting blood samples to measure serum 25(OH)D levels using an enzyme-linked immunosorbent assay (ELISA), alongside measurements of glycosylated hemoglobin (HbA1c), lipid parameters, and fasting plasma glucose. The second part comprised a detailed medical history, physical examination, and standardized neuropsychological testing using the 30-item Geriatric Depression Scale (GDS-30) and the Montreal Cognitive Assessment (MoCA). Statistical analyses used multivariable logistic regression models to identify factors independently associated with the combined presence of depressive symptoms (搜索) and MCI.
Key Findings
Serum 25-hydroxyvitamin D levels across the entire study cohort averaged 18.38 ng/mL (SD = 5.9 ng/mL). Although this mean is below 20 ng/mL, the study did not compare it with a clinical threshold or formally classify participants according to vitamin D status.
Multiple subgroup comparisons revealed significant differences across groups. The comparison group showed the highest mean concentration (22.67 ng/mL), compared with participants with depressive symptoms (搜索) alone (16.37 ng/mL, P < 0.001) or MCI alone (16.60 ng/mL, P < 0.001). The lowest vitamin D concentrations were observed in the combined depressive symptoms and MCI group (13.86 ng/mL, P < 0.001).
Separate correlation analyses showed that, in the combined group, serum vitamin D levels were negatively correlated with HbA1c concentrations (r = -0.85, P < 0.001) and GDS-30 scores (r = -0.89, P < 0.001). Serum 25(OH)D concentrations displayed a strong positive correlation with MoCA cognitive scores (r = 0.76, P < 0.001).
The multivariable model showed that lower vitamin D status remained independently associated with increased odds of having both depressive symptoms (搜索) and MCI (adjusted odds ratio [aOR] = 0.773, 95% confidence interval [CI]: 0.61–0.97, P = 0.03), alongside older age (aOR = 2.12), fewer years of formal education (aOR = 0.31), longer diabetes duration (aOR = 1.45), and higher multimorbidity burden (aOR = 3.52). Expressed another way, each 1 ng/mL increase in serum 25(OH)D was associated with approximately 23% lower adjusted odds of having both conditions.
Study Limitations and Interpretation
The authors describe the present study as the first to assess serum 25(OH)D levels and associated factors in people with T2D aged 85 years or older who had co-occurring depressive symptoms (搜索) and MCI. However, they emphasize that the findings demonstrate an association rather than a biological or causal link, and do not validate vitamin D as a neurological risk biomarker or treatment for cognitive decline.
Because vitamin D levels, depressive symptoms (搜索), and cognition were measured simultaneously, the study cannot determine which came first. Reverse causation is plausible because poorer health, frailty, reduced outdoor activity, and inadequate nutrition may contribute to lower vitamin D levels. The small subgroups, single-center population, strict exclusion criteria, and limited demographic diversity also limit the generalizability of the findings. Notably, only 38 participants had both conditions, limiting the model's complexity and stability. Residual confounding from omitted factors in the restricted multivariable model also remains possible.
Further prospective studies are needed to confirm these results and determine the temporal direction and clinical relevance of the associations. Randomized intervention trials would be required before conclusions could be drawn about supplementation or appropriate dosages, and the current findings do not support recommending vitamin D as a preventive or therapeutic strategy.